SGLT2 inhibitors and survival in lung cancer patients with diabetes
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial looks at whether a diabetes drug called an SGLT2 inhibitor can improve survival in people with both lung cancer and type 2 diabetes. If you have these two conditions, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with lung cancer and type 2 diabetes.
- You are receiving standard cancer treatment.
- Your daily activities are not severely limited (ECOG score 0-2).
- Your liver, kidneys, and heart are functioning well.
- Your doctor expects you to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medicine typically used for diabetes or weight loss (a GLP-1 drug) can help reduce side effects from the lung cancer drug lorlatinib. If you are already taking lorlatinib for your ALK-positive lung cancer and have not used a GLP-1 drug recently, you might be able to join.
This trial tests the safety of dapagliflozin (a diabetes drug) taken before surgery for stage IA lung adenocarcinoma. It may help understand if this drug can slow tumor growth while waiting for surgery.
This trial tests canagliflozin, a diabetes drug, combined with immunotherapy for people with advanced solid tumors. It may help if you have type 2 diabetes or are at risk, but you don't need diabetes to join.
This trial tests how stopping a type 2 diabetes medication called an SGLT2 inhibitor affects the liver's production of sugar and ketones. It may help understand better ways to manage diabetes.
This trial tests whether adding a new diabetes medication called chiglitazar to your current SGLT-2 inhibitor can help lower your blood sugar better. You may qualify if your blood sugar is still too high despite taking an SGLT-2 inhibitor, and this study could help find better ways to control your diabetes.
This study tests whether a type of diabetes medication called an SGLT2 inhibitor can improve the structure and function of the heart's left atrium in people with type 2 diabetes. It may help prevent heart problems in the future.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.